Skip to main content
Clinical Trials/NCT07205120
NCT07205120RecruitingNot Applicable

Fluid Guided Heart Failure Treatment

Bodyport Inc.1 site in 1 country50 target enrollmentStarted: October 8, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
50
Locations
1
Primary Endpoint
Congestion Index Alert Statistics

Study Overview

Brief Summary

FIGHT-HF is an exploratory non-randomized open-label study evaluating a heart failure management intervention.

The goal of this pilot is to assess the performance of a fluid-guided heart failure management program and Alert Response Guide (ARG) using the Bodyport Cardiac Scale and Congestion Index in 50 adult participants with acute and chronic heart failure, who are followed by a Cleveland Clinic cardiologist.

Detailed Description

This study will assess the clinical integration of the Cardiac Scale and a composite biomarker algorithm, the Congestion Index and Alert, into existing health system workflows for HF management. The data collected in this study will be used to test and refine existing Congestion Index-guided HF management protocols contained within an Alert Response Guide (ARG). The final Alert Response Guide may be further validated in future randomized control trials.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
21 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Hospitalized for acute decompensated heart failure
  • •Age 21 years or older
  • •Able to speak and read English

Exclusion Criteria

  • •New York Heart Association functional class IV symptoms
  • •Received or are scheduled to receive a heart transplant or ventricular assist - device in the next 12 months
  • •Have a glomerular filtration rate of less than 25 mL/min while nonresponsive to diuretic therapy or on chronic renal dialysis
  • •Have a history of regularly scheduled intravenous HF therapy (e.g., inotropes or diuretics)
  • •Have a life expectancy of less than 12 months
  • •Are pregnant or plan to become pregnant during the next 12 months
  • •Weigh greater than 375 lbs
  • •Unable to stand on two bare feet without assistance

Arms & Interventions

Interventional arm

Experimental

Participants will begin receiving fluid-guided care when they begin using the device in the outpatient (home) setting.

Participants will be monitored per routine clinical care and receive study follow-up visits at 45- and 90-days to assess clinical status, events, and medication changes.

Intervention: Heart Failure Management Intervention (Device)

Outcomes

Primary Outcomes

Congestion Index Alert Statistics

Time Frame: From enrollment to the end of the study duration at 90 days

Congestion Index Alert Statistics

Time Frame: From enrollment to the end of the study duration at 90 days

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Bodyport Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials